Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | PRCP | P42785 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890182 | 0.94 | HPGDS (0.40) | HPGDSSSTR3PREPGPR119JAK1 | |
| SCHEMBL889393 | 0.86 | HPGDS (0.37) | HPGDSSSTR3PREPGPR119PRCP | |
| SCHEMBL12999459 | 0.84 | HPGDS (0.47) | HPGDSSSTR3PREPGPR119PRCP | |
| SCHEMBL202934 | 0.84 | HPGDS (0.47) | HPGDSSSTR3PREPGPR119PRCP | |
| SCHEMBL18462760 | 0.84 | HPGDS (0.47) | HPGDSSSTR3PREPGPR119PRCP | |
| SCHEMBL890225 | 0.83 | CYP3A4 (0.42) | HPGDSPRCPNR1I2ABCB11CYP3A4 | |
| SCHEMBL890163 | 0.82 | CYP3A4 (0.45) | HPGDSPRCPNR1I2ABCB11CYP3A4 | |
| SCHEMBL203272 | 0.81 | HPGDS (0.44) | HPGDSSSTR3PREPGPR119PRCP | |
| SCHEMBL2708612 | 0.81 | HPGDS (0.44) | HPGDSSSTR3PREPGPR119PRCP | |
| SCHEMBL15405790 | 0.81 | HPGDS (0.44) | HPGDSSSTR3PREPGPR119PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HPGDS 2568/4885SSTR3 3284/4885PREP 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.